Vestmark Advisory Solutions’s CRISPR Therapeutics CRSP Stock Holding History

Vestmark Advisory Solutions’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$13.2M	Sell	242,266 -14,513	-6%	-$765K	0.12%	180
2026 Q1	$12.2M	Buy	256,779 +7,231	+3%	+$381K	0.14%	163
2025 Q4	$13.1M	Buy	249,548 +10,586	+4%	+$634K	0.18%	114
2025 Q3	$15.5M	Sell	238,962 -246,013	-51%	-$14.1M	0.3%	68
2025 Q2	$23.6M	Buy	484,975 +259,669	+115%	+$10M	0.34%	66
2025 Q1	$7.67M	Sell	225,306 -18,728	-8%	-$794K	0.2%	137
2024 Q4	$10.8M	Buy	244,034 +69,937	+40%	+$3.3M	0.37%	57
2024 Q3	$8.18M	Sell	174,097 -23,517	-12%	-$1.19M	0.3%	66
2024 Q2	$10.7M	Sell	197,614 -51,930	-21%	-$3M	0.45%	45
2024 Q1	$17M	Buy	249,544 +76,256	+44%	+$5.46M	0.73%	30
2023 Q4	$10.8M	Buy	+173,288	New	+$9.58M	0.55%	35

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

GSK plc London $602M AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

SOCM

SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Vestmark Advisory Solutions's CRSP Position: Q2 2026 in Review

Vestmark Advisory Solutions reduced its CRISPR Therapeutics (CRSP) stake by 5.7% in Q2 2026, selling an estimated $765K and leaving 242,266 shares worth $13.2M. The position accounts for 0.12% of the portfolio, ranked #180.

Vestmark Advisory Solutions first reported a position in CRSP in Q4 2023 and has held it in 11 quarters since. The position peaked at $23.6M in Q2 2025. 522 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

Vestmark Advisory Solutions held 242,266 shares of CRISPR Therapeutics worth $13.2M as of Q2 2026.
Vestmark Advisory Solutions sold 14,513 CRISPR Therapeutics shares in Q2 2026, an estimated $765K.
CRISPR Therapeutics made up 0.12% of Vestmark Advisory Solutions's portfolio in Q2 2026, its #180 holding.
Vestmark Advisory Solutions first reported a position in CRISPR Therapeutics in Q4 2023 and has held it in 11 quarters since.
Vestmark Advisory Solutions's CRISPR Therapeutics position peaked at $23.6M in Q2 2025.
522 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Vestmark Advisory Solutions's 13F filing for Q2 2026, filed 14 Aug 2026.